ClinicalTrials HQ

A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

Recruiting · NCT06422923 · Registry updated 2026-01-07
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)Epileptic Syndromes, brain disorder, central nervous system disorder, epilepsy, focal epilepsy, nervous system disorder, temporal lobe epilepsyRecruitingPhase 1 / Phase 22026-01-07NCT06422923

1 results · Page 1 of 1

Organizations

Swipe the table sideways for more columns.

OrganizationsLinked trials
Neurona Therapeutics2

17 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Atrium HealthCharlotteUnited States23
Duke University HospitalDurhamUnited States54
Medical College of WisconsinMilwaukeeUnited States483
Oregon Health and Science UniversityPortlandUnited States382
Stanford UniversityPalo AltoUnited States161
SUNY Upstate Medical UniversitySyracuseUnited States68
UC Irvine Medical CenterOrangeUnited States19
University of Arkansas for Medical SciencesLittle RockUnited States218
University of California San DiegoSan DiegoUnited States20
University of California San FranciscoSan FranciscoUnited States144
University of ChicagoChicagoUnited States312
University of Colorado Anschutz Medical CampusAuroraUnited States142
University of Iowa Health CareIowa CityUnited States47
University of Southern California Keck HospitalLos AngelesUnited States2
UTHealth HoustonHoustonUnited States17
UVA Health University Medical CenterCharlottesvilleUnited States2
Wake Forest Baptist Medical CenterWinston-SalemUnited States25